Andrew Berens's questions to Beigene Ltd (ONC) leadership • Q4 2024
Question
Andrew Berens of Leerink Partners questioned the company's expectations for its gastric cancer trial readout, its commitment to breast cancer development, and whether it is observing or expecting off-label use of BRUKINSA in fixed-duration regimens.
Answer
Global Head of R&D Lai Wang stated the gastric cancer trial aims to broaden the tislelizumab label, with a readout expected in H2 2025. General Manager of North America Matt Shaulis addressed off-label use, noting that while BRUKINSA has a strong profile, it lacks combination approval or NCCN guideline listings for such use, though he acknowledged recent data from the BOVIN study was notable.